Total
0
Shares
Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • B2C website has launched for HeraMED’s medical grade foetal heart rate monitor called HeraBEAT
  • HeraBEAT allows parents to monitor its unborn child’s heart rate from the comfort of their own home providing relief and cost-efficiency
  • A marketing campaign will launch on 26 June 2019 to drive product awareness
  • The campaign is developed and led by Meerkats – a creative agency

HeraMED Limited has just launched its business-to-consumer (B2C) website for its foetal heart rate monitor called HeraBEAT.

HeraBEAT is a revolutionary smartphone technology allowing parents to monitor their unborn child’s heart rate from anywhere, at anytime. The heart rate monitor has received highly positive reviews from soon-to-be mums who trialled the product.

The reaction from soon-to-be mums has been positive with most women expressing their relief knowing they can monitor the baby between check ups and in the comfort of their own home.

The company will launch a marketing campaign on the 26 June 2019 which will be led by HeraMED’s partner, Meerkats. Meerkats is a creative agency with over 15 years of experience and has serviced brands including St John Ambulance and iiNet.

HeraMED CEO and Co-founder, David Groberman said: “We have worked closely with Meerkats to define a strategy that will drive device uptake and increase awareness of HeraMED from a consumer standpoint and with medical organisations,”

HeraMED, Meerkats and baby products supplier Dale Group International, have collaborated to design the marketing and engagement strategy and ensuring cost efficiency for potential future customers.

The company is confident the marketing campaign will build awareness with consumers and medical organisations and initiate HeraBEAT sales.

Whilst HeraBEAT isn’t yet for sale to the general public, parents and families who are interested can visit the website and pre-register for the product. More updates will be released in coming weeks.

HMD by the numbers
More From The Market Herald
Biogene Technology (ASX:BGT) - CEO, Richard Jagger

" Bio-Gene (ASX:BGT) shares close green on new commercial deal

Bio-Gene Technology (BGT) has executed a licence and development agreement with Evergreen Garden Care.
Beam Communications (ASX:BCC) - Chairman, Simon Wallace

" Beam Communications (ASX:BCC) receives orders for 12,000 ZOLEO units

Beam Communications (BCC) has received orders for 12,000 extra ZOLEO devices manufactured under its joint venture entity.
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito

" Botanix Pharmaceuticals (ASX:BOT) progresses clinical programs

Botanix Pharmaceuticals (BOT) progressed a number of clinical programs during the September quarter.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham

" Recce Pharmaceuticals (ASX:RCE) receives ethics approval to begin R327 trial

Recce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin its phase one intravenous (IV) trial of RECCE327 (R327).